Search clinical trials for: Camrelizumab ＋Immunotherapy

Total 964 results

Beijing Tsinghua Chang Gung Hospital

Unknown

Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer

Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

Unresectable/Metastatic Colorectal Cancer

China
Sun Yat-sen University
Chongqing University Cancer Hospital; Jiangxi Provincial Cancer Hospital; Shenzhen... and other collaborators

Recruiting

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Nanfang Hospital of Southern Medical University

Recruiting

Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC

Hepatocellular Carcinoma

China
Henan Cancer Hospital

Recruiting

Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer (CAMERA)

Small Cell Lung Carcinoma

China
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma

Glioblastoma

China
Chinese PLA General Hospital

Recruiting

Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Hodgkin Lymphoma

China
Chinese PLA General Hospital

Recruiting

Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor

Non Hodgkin Lymphoma

China
Shanghai Pulmonary Hospital, Shanghai, China

Active, not recruiting

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Hepatocellular Carcinoma (HCC)

China
Sichuan University

Not yet recruiting

The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC

Carrelizumab Plus Lenvatinib Combined With TACE | Borderline Resectable Hepatocellular Carcinoma

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma

Advanced Gastric Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma

Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Advanced NSCLC

China
Zhiyong Huang
Wuhan University; Hubei Cancer Hospital; Wuhan Union Hospital, China; Renmin Hospital... and other collaborators

Recruiting

Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension

Unresectable Hepatocellular Carcinoma

China
Chinese PLA General Hospital

Recruiting

An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma

Lymphoma | Solid Tumor

China
Zhejiang University

Active, not recruiting

Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC

Hepatocellular Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer

Locally Advanced Non-small Cell Lung Cancer

China
ShiCang Yu

Recruiting

Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer

Colorectal Cancer

China
Tianjin Medical University Cancer Institute and...
The First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaborators

Completed

Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC. (REICRAE)

Metastatic Esophageal Squamous Cell Carcinoma

China
Zhejiang University

Terminated

Perioperative Therapy for Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Allergopharma GmbH & Co. KG

Completed

Multicenter Trial of Immunotherapy With House Dust Mite Allergoid (ACRI)

Rhinoconjunctivitis

Germany
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer

Esophageal Cancer | Surgery | Immunotherapy | Chemoradiotherapy | Induction Therapy

China
Varian, a Siemens Healthineers Company

Active, not recruiting

Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer (ARTIA-Lung)

Stage III Non-small Cell Lung Cancer

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC

Chemotherapy Effect | BCLC Stage C Hepatocellular Carcinoma

China
Xuanwu Hospital, Beijing

Recruiting

Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma

Chordoma | Chemotherapy Effect

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Apatinib Mesylate

Solid Tumor

China
Sun Yat-sen University

Completed

SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

Recurrent Cervical Carcinoma | Metastatic Cervical Cancer

China
Guangxi Medical University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC

Hepatocellular Carcinoma

China
Nanfang Hospital of Southern Medical University

Recruiting

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Not yet recruiting

Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma
The First Affiliated Hospital of Xiamen University

Not yet recruiting

Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC

Lung Neoplasms
The First Affiliated Hospital of Soochow University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT

Acute Myeloid Leukemia

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

Stage III Hepatocellular Cancer (CNLC Staging)

China
Hunan Cancer Hospital
Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Recruiting

A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).

Hepatocellular Carcinoma | Immune Checkpoint Inhibitors

China
Peking University First Hospital

Not yet recruiting

Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma

Renal Cell Carcinoma
ShiYue Li

Unknown

Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer (CCA-MPLC)

Lung Cancer
Zhejiang University
Huashan Hospital; West China Hospital; The First Affiliated Hospital of Zhengzhou... and other collaborators

Unknown

Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

Hepatocellular Carcinoma | Liver Transplant

China
University of North Carolina, Chapel Hill
Genentech, Inc.

Completed

Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy (PAIE/Xolair)

Peanut Hypersensitivity

United States
Changzhou No.2 People's Hospital

Not yet recruiting

FMT+SOX+Sintilimab as First-line Treatment for Advanced Gastric Cancer

Gastric Cancer
Peking University Third Hospital

Not yet recruiting

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

Locally Advanced Pancreatic Cancer
Health Science Center of Xi'an Jiaotong University

Recruiting

Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer

Ovarian Cancer | Cancer of the Ovary | Ovarian Neoplasm | Ovary Cancer | Neoplasms, Ovarian | Ovary Neoplasms | Ovary Neoplasm | Cancer of Ovary | Cancer, Ovarian | Ovarian Cancers | Neoplasm, Ovarian | Neoplasm, Ovary | Neoplasms, Ovary | Cancer, Ovarian Stromal | Cancers, Ovary | Ovary Cancers | Cancers, Ovarian

China
University Hospital, Ghent
Kom Op Tegen Kanker

Recruiting

Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients With Muscle Invasive Bladder Cancer (EFFORT-MIBC)

Muscle-Invasive Bladder Carcinoma

Belgium
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern... and other collaborators

Recruiting

Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | De-escaltion Therapy

China
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Massachusetts General Hospital

Enrolling by invitation

Food Oral Immunotherapy for Peanut Allergy

Peanut Allergy

United States
Pfizer

Terminated

Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC

Non-Small Cell Lung Cancer | Triple-negative Breast Cancer

United States
Shandong Cancer Hospital and Institute
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma

China
HRYZ Biotech Co.

Recruiting

MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma

Sarcoma

China

Search clinical trials for: Camrelizumab ＋Immunotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations